AC Immune SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by AC Immune SA for the month of August 2021, dated August 4, 2021. The registrant is headquartered in Lausanne, Switzerland, and files annual reports under Form 20-F. The filing incorporates by reference interim financial statements and a press release.
Key Financial Metrics
The filing text provided is a cover sheet and exhibit index; it does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are located in the incorporated exhibits (Exhibit 99.1 and 99.2) which are not included in the source text.
Material Changes and Transactions
The filing discloses the execution of the following material agreements, details of which are redacted in the exhibit index:
- Asset Purchase and Contribution in Kind Agreement (Exhibit 10.1).
- Convertible Note Agreement with Santo Venture GmbH (Exhibit 10.2).
- Convertible Note Agreement with FCPB Affi GmbH (Exhibit 10.3).
Portions of these exhibits are redacted as the company determined the omitted information is not material but could cause competitive harm if disclosed.
Guidance, Outlook, and Risks
The filing references a Press Release dated August 4, 2021 (Exhibit 99.3) and Management's Discussion and Analysis (Exhibit 99.2), which would contain guidance, outlook, and risk factors. The cover sheet text itself does not provide specific commentary on future performance or contingencies.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific financial impact of the six months ended June 30, 2021.
- Examine the redacted portions of Exhibits 10.1, 10.2, and 10.3 to understand the terms of the asset purchase and convertible notes.
- Read Exhibit 99.3 (Press Release) for management's commentary on the strategic significance of the new agreements.
- Verify the dilution impact of the convertible notes issued to Santo Venture GmbH and FCPB Affi GmbH.